Why Novo Nordisk Stock Slipped Today
Novo Nordisk (NYSE: NVO) stock imitated the company's leading product on Wednesday by slimming down in price. The Danish pharmaceutical's shares lost nearly 4% of their value following its latest earnings release, comparing unfavorably to the modest (0.7%) gain of the S&P 500 index.
Novo Nordisk, famous for its Wegovy obesity drug (and its sibling, diabetes treatment Ozempic), unveiled its first half and second quarter of 2025 figures early Wednesday morning.
Image source: Getty Images.
Source Fool.com
